|
|
|
| Effect of estradiol valerate combined with dydrogesterone for treating women with climacteric syndrome and its influence on immune function, sex hormone levels, and endometrial thickness |
| The Fifth People's Hospital of Chengdu, Sichuan Province, 611130 |
|
|
|
|
Abstract To investigate the effect of estradiol valerate combined with dydrogesterone for treating women with climacteric syndrome, and to study its influence on immune function, sex hormone levels, endometrial thickness, and bone mineral density of the women. Methods: 165 women with climacteric syndrome were divided into study group (n=84) and control group (n=81) by random number table method between February 2017 and September 2019. The women in the control group were treated with estradiol valerate, and the women in the study group were treated with estradiol valerate combined with dydrogesterone. The curative effect of the women, and the influence on the immune function, the sex hormone levels, and the endometrial thickness of the women in the two groups were analyzed. Results: After treatment, the efficacy (94.1%) of the women in the study group was significant higher than that (81.0%) of the women in the control group. The values of the immune indexes, such as CD3+, CD4+ and CD4+/CD8+ of the women in both groups had increased significantly, but the value CD8+ of the women in both groups had decreased significantly, and the change range of the women in the study group was significant more than that of the women in the control group. The endometrial thickness (5.15±0.12mm) of the women in the study group was significant higher than that (5.03± 0.23mm) of the women in the control group, and the bone mineral density values of bilateral femur and L1-4 level of the women in the study group were significant higher than those of the women in the control group. The levels of inflammatory factors of the women in the study group were significant lower than those of the women in the control group. The levels of follicle stimulating hormone and luteinizing hormone of the women in the study group were significant lower than those of the women in the control group, but the levels of estradiol and progesterone of the women in the study group were significant higher (all P＜0.05). Conclusion: Estradiol valerate combined with dydrogesterone for treating women with climacteric syndrome, which can significantly relieve their clinical symptoms, improve their immune function, increase their sex hormone levels, and promote the recovery of their endometrial thickness.
|
|
|
|
|
|
|
|
|
